New combo therapy shows promise in slowing breast cancer

NCT ID NCT01658462

Completed Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drug nintedanib to standard chemotherapy (docetaxel) helps people with advanced HER2-negative breast cancer live longer without their disease getting worse. Fifty-one adults who had already received some treatment took part. The goal was to see if the combination worked better than chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

CH Compiègne-Noyon

Compiègne, 60200, France
CHU Amiens- Hôpital Sud

Amiens, 80 054, France
CMCO de la Côte d'Opale

Saint-Martin-Boulogne, 62280, France
Centre Alexis Vautrin

Vandœuvre-lès-Nancy, 54 500, France
Centre Léonard de Vinci

Dechy, 59 187, France
Centre Oscar Lambret

Lille, 59 020, France
Centre Pierre Curie

Beuvry, 62660, France
Hôpital Bretonneau

Tours, 37044, France
Hôpital Privé les Bonnettes

Arras, 62000, France
Institut Jean Godinot

Reims, 51056, France
Nouvelle Clinique des Dentellières

Valenciennes, 59300, France
Polyclinique de Limoges - site Chénieux

Limoges, 87039, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.